Exploratory prospective clinical study on predictors of efficacy of immune checkpoint inhibitors and immune-related adverse events in early-stage breast cancer
Not Applicable
Recruiting
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000050985
- Lead Sponsor
- Showa university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
2) Patients who have not given consent to this study 3) Patients who also have other malignant tumors 4) Bilateral breast cancer 5) history of malignant tumor
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To verify whether it is possible to predict the pCR and irAE of ICI combination therapy from microbiome in early-stage TNBC.
- Secondary Outcome Measures
Name Time Method Presence or absence of changes in intestinal flora due to ICI administration Relationship between microbiome and IOscore